MX2021014015A - Metodos basados en el genoma para reducir el riesgo cardiovascular. - Google Patents
Metodos basados en el genoma para reducir el riesgo cardiovascular.Info
- Publication number
- MX2021014015A MX2021014015A MX2021014015A MX2021014015A MX2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A MX 2021014015 A MX2021014015 A MX 2021014015A
- Authority
- MX
- Mexico
- Prior art keywords
- cardiovascular risk
- genome
- based methods
- reduce cardiovascular
- pcsk9 inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Data Mining & Analysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Software Systems (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849670P | 2019-05-17 | 2019-05-17 | |
| US201962933181P | 2019-11-08 | 2019-11-08 | |
| PCT/US2020/033315 WO2020236670A1 (en) | 2019-05-17 | 2020-05-16 | Genome-based methods for reducing cardiovascular risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014015A true MX2021014015A (es) | 2022-02-21 |
Family
ID=70978651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014015A MX2021014015A (es) | 2019-05-17 | 2020-05-16 | Metodos basados en el genoma para reducir el riesgo cardiovascular. |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12264366B2 (https=) |
| EP (2) | EP3969620B1 (https=) |
| JP (2) | JP2022532423A (https=) |
| CA (1) | CA3139943A1 (https=) |
| MX (1) | MX2021014015A (https=) |
| WO (1) | WO2020236670A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116171161A (zh) | 2020-08-25 | 2023-05-26 | 雷杰纳荣制药公司 | 用pcsk9和ldlr调节剂治疗败血症 |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057459A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| EP2158330A2 (en) * | 2007-05-11 | 2010-03-03 | Tufts Medical Center | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| JP5526122B2 (ja) | 2008-04-18 | 2014-06-18 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 主要有害心イベントのリスクを予測する方法 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN102596249A (zh) | 2009-10-30 | 2012-07-18 | 默沙东公司 | Ax1和ax189 pcsk9拮抗剂和变体 |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| JP5932670B2 (ja) | 2010-03-11 | 2016-06-08 | ライナット ニューロサイエンス コーポレイション | ｐＨ依存性の抗原結合を有する抗体 |
| SG192117A1 (en) | 2011-01-28 | 2013-08-30 | Sanofi Sa | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| JP2015507205A (ja) * | 2012-02-12 | 2015-03-05 | ビージー メディシン，インコーポレイテッド | 有害事象のリスク因子および予測 |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP2861624A1 (en) | 2012-06-15 | 2015-04-22 | F. Hoffmann-La Roche AG | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
| US9540449B2 (en) | 2012-08-13 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
| JP6450679B2 (ja) | 2012-08-21 | 2019-01-09 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | マルチマーカーリスク層別化 |
| CN105473141A (zh) | 2013-03-15 | 2016-04-06 | 实发生物医学公司 | 治疗和/或预防心血管疾病的抗pcsk9化合物和方法 |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US10337070B2 (en) * | 2017-01-12 | 2019-07-02 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| US20190017119A1 (en) * | 2017-07-12 | 2019-01-17 | The General Hospital Corporation | Genetic Risk Predictor |
-
2020
- 2020-05-16 EP EP20730885.9A patent/EP3969620B1/en active Active
- 2020-05-16 JP JP2021568564A patent/JP2022532423A/ja active Pending
- 2020-05-16 EP EP25181054.5A patent/EP4640848A3/en active Pending
- 2020-05-16 MX MX2021014015A patent/MX2021014015A/es unknown
- 2020-05-16 CA CA3139943A patent/CA3139943A1/en active Pending
- 2020-05-16 US US16/876,030 patent/US12264366B2/en active Active
- 2020-05-16 WO PCT/US2020/033315 patent/WO2020236670A1/en not_active Ceased
-
2025
- 2025-02-26 US US19/064,447 patent/US20250257406A1/en active Pending
- 2025-12-04 JP JP2025229455A patent/JP2026062658A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210002724A1 (en) | 2021-01-07 |
| EP4640848A2 (en) | 2025-10-29 |
| JP2026062658A (ja) | 2026-04-10 |
| US20250257406A1 (en) | 2025-08-14 |
| US12264366B2 (en) | 2025-04-01 |
| EP3969620A1 (en) | 2022-03-23 |
| EP3969620B1 (en) | 2025-06-25 |
| WO2020236670A1 (en) | 2020-11-26 |
| CA3139943A1 (en) | 2020-11-26 |
| EP4640848A3 (en) | 2026-01-14 |
| JP2022532423A (ja) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123369T1 (el) | Συνθεσεις και μεθοδοι για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α) | |
| CO2018003678A2 (es) | Composiciones y métodos para inhibir la expresión génica de lpa | |
| MX2022007754A (es) | Nuevos agonistas de il2 y metodos de uso de estos. | |
| BR112022003527A2 (pt) | Cianopirrolidinas substituídas com atividade como inibidores de usp30 | |
| ECSP21033236A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CY1123367T1 (el) | Μεθοδοι και συνθεσεις για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α) | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| CL2024001693A1 (es) | Métodos, sistemas y equipos para el tratamiento de enfermedades inflamatorias dirigidas al tl1a. | |
| BR112013020798A2 (pt) | terapia de combinação do inibidor mtor /jak | |
| MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2018005925A (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| CR20150242A (es) | Terapia adyuvante con inhibidores de quinasa de la familia tec | |
| MX2018004614A (es) | Metodos para preparar celulas t para terapia de celulas t. | |
| PH12014501491A1 (en) | Subcutaneous therapeutic use of dpp-4 inhibitor | |
| MX363949B (es) | Inhibidor de quinasa. | |
| MX2016000696A (es) | Compuestos terapeuticos activos y sus usos. | |
| NZ594365A (en) | Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders | |
| MX2014000292A (es) | Usos de inhibidores etiquetados hsp90. | |
| CL2015002807A1 (es) | Terapia de combinación | |
| BR112015029240A2 (pt) | composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo | |
| MY201580A (en) | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor | |
| NI201700065A (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3, 2-d]pirimidin-4-onas como inhibidores de mielopiroxidasa | |
| ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| MX2022001004A (es) | Inhibidores de enzimas. |